S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist

Werewolf Therapeutics (HOWL) Stock Forecast, Price & News

$2.84
+0.33 (+13.15%)
(As of 05/26/2023 03:59 PM ET)
Compare
Today's Range
$2.55
$2.90
50-Day Range
$2.17
$3.04
52-Week Range
$1.39
$7.51
Volume
37,000 shs
Average Volume
203,703 shs
Market Capitalization
$101.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.10

Werewolf Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
290.8% Upside
$11.10 Price Target
Short Interest
Healthy
0.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.42) to ($1.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

250th out of 1,010 stocks

Pharmaceutical Preparations Industry

105th out of 494 stocks


HOWL stock logo

About Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

Werewolf Therapeutics (NASDAQ:HOWL) PT Raised to $10.00
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Expert Ratings for Werewolf Therapeutics
Analyst Ratings for Werewolf Therapeutics
Werewolf Therapeutics (NASDAQ:HOWL) PT Lowered to $15.00
See More Headlines
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Company Calendar

Last Earnings
11/10/2021
Today
5/29/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
39
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.10
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.30
Forecasted Upside/Downside
+290.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-53,810,000.00
Net Margins
-241.79%
Pretax Margin
-241.79%

Debt

Sales & Book Value

Annual Sales
$16.40 million
Book Value
$3.98 per share

Miscellaneous

Free Float
13,283,000
Market Cap
$101.13 million
Optionable
Not Optionable
Beta
0.20

Key Executives

  • Dr. Daniel J. Hicklin Ph.D. (Age 58)
    Founder, CEO, Pres, Sec. & Director
    Comp: $762.87k
  • Mr. Timothy W. Trost CPA (Age 64)
    CFO, Treasurer & Assistant Sec.
    Comp: $511.88k
  • Dr. Chulani Karunatilake Ph.D.
    Chief Technology Officer
  • Dr. Reid Leonard Ph.D. (Age 63)
    Chief Operating Officer
  • Dr. Cynthia Seidel-Dugan Ph.D. (Age 63)
    Chief Scientific Officer
  • Dr. Randi Isaacs M.D. (Age 66)
    Chief Medical Officer
  • Ms. Ellen A. Lubman M.B.A. (Age 46)
    Chief Bus. Officer













HOWL Stock - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings
or view top-rated stocks.

What is Werewolf Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued twelve-month price objectives for Werewolf Therapeutics' stock. Their HOWL share price forecasts range from $8.30 to $15.00. On average, they anticipate the company's stock price to reach $11.10 in the next twelve months. This suggests a possible upside of 290.8% from the stock's current price.
View analysts price targets for HOWL
or view top-rated stocks among Wall Street analysts.

How have HOWL shares performed in 2023?

Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 38.5% and is now trading at $2.84.
View the best growth stocks for 2023 here
.

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HOWL earnings forecast
.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 241.79% and a negative trailing twelve-month return on equity of 40.02%.

When did Werewolf Therapeutics IPO?

(HOWL) raised $101 million in an initial public offering on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Werewolf Therapeutics' stock symbol?

Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL."

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rubric Capital Management LP (5.45%), Alyeska Investment Group L.P. (1.12%), Acadian Asset Management LLC (0.22%), Schonfeld Strategic Advisors LLC (0.21%), HBK Sorce Advisory LLC (0.15%) and State Street Corp (0.14%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends
.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Werewolf Therapeutics' stock price today?

One share of HOWL stock can currently be purchased for approximately $2.84.

How much money does Werewolf Therapeutics make?

Werewolf Therapeutics (NASDAQ:HOWL) has a market capitalization of $101.13 million and generates $16.40 million in revenue each year. The company earns $-53,810,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How can I contact Werewolf Therapeutics?

Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The official website for the company is werewolftx.com. The company can be reached via phone at 617-952-0555 or via email at ir@werewolftx.com.

This page (NASDAQ:HOWL) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -